Shattuck Labs, Inc. Payments for (Proceeds from) Available-for-sale Securities, Short-term
Shattuck Labs, Inc. (STTK) reported Payments for (Proceeds from) Available-for-sale Securities, Short-term of -$55.40 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm · last filed 2023-11-09
- Shattuck Labs, Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2023-09-30 was $14.53M.
- Shattuck Labs, Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2023-06-30 was -$24.73M.
- Shattuck Labs, Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2023-03-31 was -$45.20M, a 450.55% decline year-over-year.
- Shattuck Labs, Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2022-09-30 was -$30.68M.
| Period end | Payments for (Proceeds from) Available-for-sale Securities, Short-term 3 month | Payments for (Proceeds from) Available-for-sale Securities, Short-term 6 month | Payments for (Proceeds from) Available-for-sale Securities, Short-term 9 month |
|---|---|---|---|
| 2023-09-30 | $14.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$10.20M derived: sum of 2 quarters · filed 2023-11-09 | -$55.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$24.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$69.93M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$45.20M 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | -$30.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$41.79M derived: sum of 2 quarters · filed 2023-11-09 | -$28.90M 10-Q · filed 2023-11-09 |
| 2022-06-30 | -$11.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.78M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $12.89M 10-Q · filed 2023-05-09 | ||
| 2021-09-30 | -$12.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$29.38M derived: sum of 2 quarters · filed 2022-11-09 | $30.11M 10-Q · filed 2022-11-09 |
| 2021-06-30 | -$17.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $42.31M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $59.49M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |